Chinese Clinical Oncology

SJR Rank #9,237H-index: 44SJR: 0.636Best quartile: Q2Open AccessListed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

AME Publishing Company

Country

Hong Kong

Type

journal

SJR by Edition

2022202500.20.40.60.8

Subject Categories

  • Medicine (miscellaneous)Q2
  • OncologyQ3

Areas: Medicine

Most published research topics

Lung Cancer Treatments and MutationsGastric Cancer Management and OutcomesCancer, Hypoxia, and MetabolismHepatocellular Carcinoma Treatment and PrognosisLung Cancer Diagnosis and TreatmentLung Cancer Research StudiesColorectal Cancer Treatments and StudiesCancer Mechanisms and TherapyCancer Treatment and PharmacologyCholangiocarcinoma and Gallbladder Cancer Studies

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs055110165220

Documents per Year

202220250255075100

Detailed Information

ISSN

2304-3873, 2304-3865

SJR Best Quartile

Q2

Region

Asiatic Region

Citations per Document (2 years)

1.94

References per Document

43.67

Coverage

2012-2026

Scope

The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO) publishes articles that describe new findings in the field of oncology, and provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to: multimodality therapy, biomarkers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field. To that end, Chin Clin Oncol is dedicated to translating the latest research developments into best multimodality practice. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of cancer subjects.

Metrics from SCImago Journal Rank 2025. View on SCImago